Stock Analiz

Agios Pharmaceuticals, Inc. (AGIO) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Agios Pharmaceuticals’s revenue went from $70M in fiscal 2016 to $54M in fiscal 2025, a decline of about 2.8% a year.

Net income in fiscal 2025 was -$413M, a net margin of -764.0%; the best year in this period was 2021 with $1.6B.

Over the twelve months to September 30, 2026, revenue was $141M and net income -$373M.

Free cash flow was -$377M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 48% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $70M20162017: $43M20172018: $94M20182019: $118M20192020: $020202022: $14M20222023: $27M20232025: $54M2025$54M
Net income
2016: -$198M162017: -$315M172018: -$346M182019: -$411M192020: -$327M202021: $1.6B212022: -$232M222023: -$352M232024: $674M242025: -$413M25-$413M
Free cash flow
2016: $29M162017: -$290M172018: -$311M182019: -$383M192020: -$305M202021: -$413M212022: -$314M222023: -$297M232024: -$392M242025: -$377M25-$377M
EPS (diluted)
2016: $-5.07162017: $-6.75172018: $-6.03182019: $-6.86192020: $-4.74202021: $26.55212022: $-4.23222023: $-6.33232024: $11.64242025: $-7.1225$-7.12

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$141M$54M—$27M$14M—$0$118M$94M$43M$70M
Gross profit$132M$48M—$24M$13M—$0$117M$93M$43M$70M
Operating income-$419M-$472M-$426M-$391M-$389M-$378M-$336M-$316M-$362M-$321M-$201M
Net income-$373M-$413M$674M-$352M-$232M$1.6B-$327M-$411M-$346M-$315M-$198M
EPS (diluted)$-6.32$-7.12$11.64$-6.33$-4.23$26.55$-4.74$-6.86$-6.03$-6.75$-5.07
R&D$343M$340M$301M$296M$280M$257M$221M$214M$341M$293M$220M
Revenue growth———+88.4%——−100.0%+24.9%+119.4%−38.5%+18.2%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$332M-$373M-$390M-$296M-$309M-$407M-$291M-$371M-$304M-$285M$39M
Capital spending-$4M-$4M-$2M-$999000-$5M-$6M-$14M-$12M-$7M-$5M-$10M
Free cash flow-$336M-$377M-$392M-$297M-$314M-$413M-$305M-$383M-$311M-$290M$29M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———$0$0$802M$0$0———
Stock-based pay$62M$53M$43M$45M$49M$54M$62M$58M$73M$48M$42M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$854M$894M$777M$783M$1.0B$573M$565M$585M$103M$541M
Debt—$40M$57M$72M$86M$96M$105M$113M$0$0$0
Equity—$1.2B$1.5B$811M$1.1B$1.3B$400M$641M$688M$376M$359M
Total assets—$1.3B$1.7B$937M$1.2B$1.4B$853M$891M$858M$614M$619M
Shares (diluted)60M58M58M56M55M60M69M60M57M47M39M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin93.8%88.3%—89.3%88.0%——98.9%98.5%100.0%100.0%
Operating margin-297.7%-873.9%—-1459.5%-2732.1%——-268.2%-384.0%-745.8%-287.6%
Net margin-264.8%-764.0%—-1312.6%-1627.8%——-349.0%-366.6%-731.6%-284.0%
FCF margin-238.5%-698.3%—-1107.5%-2207.6%——-324.5%-329.9%-673.9%41.0%
ROIC—-38.2%-25.0%-44.3%-32.8%-21.5%-52.6%-42.0%-52.7%-85.4%-56.0%
ROE—-34.6%43.7%-43.4%-21.1%124.2%-81.9%-64.2%-50.3%-83.8%-55.4%

Frequently asked questions

What is Agios Pharmaceuticals’s annual revenue?

$54M in fiscal 2025 and $141M over the twelve months to September 30, 2026.

How much profit does Agios Pharmaceuticals make?

Net income was -$413M in fiscal 2025 (net margin -764.0%).

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.